PMID- 31814488
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 130
IP  - 7
DP  - 2020 Jul
TI  - A proof-of-principle study of the short-term effects of 
      3,4-methylenedioxymethamphetamine (MDMA) on tinnitus and neural connectivity.
PG  - 671-682
LID - 10.1080/00207454.2019.1702544 [doi]
AB  - Background: This study was conducted to investigate the short-term behavioural 
      and neurophysiological effects of 3,4-methylenedioxymethamphetamine (MDMA) on 
      tinnitus perception.Methods: A double-blind randomized controlled cross-over 
      design. Part 1. Behavioural measures of tinnitus following 30 mg MDMA or placebo 
      administration (N = 5 participants) and Part 2. Behavioural measures of tinnitus 
      and correlations between pairs of apriori regions of interest (ROI) using 
      resting-state functional magnetic resonance imaging (rs-fMRI) before and after 
      70 mg of MDMA or placebo (N = 8 participants).Results: The results to MDMA were 
      similar to placebo. For the 70 mg dose, there was a significant reduction after 
      4 h in annoyance and ignore ratings. RsMRI showed decreased connectivity compared 
      with placebo administration between the left hippocampal, right hippocampal, left 
      amygdala and right amygdala regions, and between the right posterior 
      parahippocampal cortex and the left amygdala after two hours of 70 mg MDMA 
      administration. Increased connectivity compared to placebo administration was 
      found post MDMA between the right post-central gyrus and right posterior and 
      superior temporal gyrus, and between the thalamus and frontoparietal 
      network.Conclusions: Following 70 mg of MDMA two tinnitus rating scales 
      significantly improved. There was, however, a placebo effect. Compared with 
      placebo the rsMRI following the MDMA showed reductions in connectivity between 
      the amygdala, hippocampus and parahippocampal gyrus. There is sufficient proof of 
      concept to support future investigation of MDMA as a treatment for tinnitus.
FAU - Searchfield, G D
AU  - Searchfield GD
AD  - Eisdell Moore Centre & Audiology Section, The University of Auckland, Auckland, 
      New Zealand.
AD  - Centre for Brain Research, The University of Auckland, Auckland, New Zealand.
AD  - Brain Research New Zealand, Auckland, New Zealand.
FAU - Poppe, T N E R
AU  - Poppe TNER
AD  - Biomedical Engineering and Imaging Sciences, Kings College London, London, UK.
FAU - Durai, M
AU  - Durai M
AD  - Eisdell Moore Centre & Audiology Section, The University of Auckland, Auckland, 
      New Zealand.
AD  - Centre for Brain Research, The University of Auckland, Auckland, New Zealand.
FAU - Jensen, M
AU  - Jensen M
AD  - Pharmacy, Whakatane Hospital, Bay of Plenty, School of Pharmacy, University of 
      Auckland, Auckland, New Zealand.
FAU - Kennedy, M A
AU  - Kennedy MA
AUID- ORCID: 0000-0002-6445-8526
AD  - Department of Pathology and Biomedical Science, University of Otago, 
      Christchurch, New Zealand.
FAU - Maggo, S
AU  - Maggo S
AD  - Department of Pathology and Biomedical Science, University of Otago, 
      Christchurch, New Zealand.
FAU - Miller, A L
AU  - Miller AL
AD  - Department of Pathology and Biomedical Science, University of Otago, 
      Christchurch, New Zealand.
FAU - Park, J
AU  - Park J
AD  - Eisdell Moore Centre & Audiology Section, The University of Auckland, Auckland, 
      New Zealand.
FAU - Russell, B R
AU  - Russell BR
AD  - School of Pharmacy, University of Otago, Dunedin, New Zealand.
FAU - Shekhawat, G S
AU  - Shekhawat GS
AD  - Auckland University of Technology, Auckland, New Zealand.
FAU - Spiegel, D
AU  - Spiegel D
AD  - Eisdell Moore Centre & Audiology Section, The University of Auckland, Auckland, 
      New Zealand.
FAU - Sundram, F
AU  - Sundram F
AD  - Department of Psychological Medicine, Faculty of Medical and Health Sciences, The 
      University of Auckland, Auckland, New Zealand.
FAU - Wise, K
AU  - Wise K
AUID- ORCID: 0000-0001-7571-230X
AD  - Auckland University of Technology, Auckland, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200106
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (Psychotropic Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Brain/*drug effects/physiopathology
MH  - Brain Mapping
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Neural Pathways/drug effects/physiopathology
MH  - Psychotropic Drugs/*administration & dosage
MH  - Tinnitus/*drug therapy/physiopathology
OTO - NOTNLM
OT  - 3,4-methylenedioxymethamphetamine
OT  - Tinnitus
OT  - rs-MRI
OT  - treatment
EDAT- 2019/12/10 06:00
MHDA- 2021/04/07 06:00
CRDT- 2019/12/10 06:00
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2019/12/10 06:00 [entrez]
AID - 10.1080/00207454.2019.1702544 [doi]
PST - ppublish
SO  - Int J Neurosci. 2020 Jul;130(7):671-682. doi: 10.1080/00207454.2019.1702544. Epub 
      2020 Jan 6.